|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Supplementary table S3: Renal mRNA expression levels of MCP-1 and F4/80 in both models normalized for placebo-treated mice | | | | |
| marker | **SHAM** | **placebo** | **finerenone**  **10 mg/kg** | **empagliflozin**  **30 mg/kg** |
| UUO model (day 10) | | | | |
| F4/80 | 8.6 ± 0.6\*\*\*\* | 100.0 ± 30.3 | 106.2 ± 41.1 | 124.6 ± 32.2 |
| MCP-1 | 3.0 ± 0.8\*\*\*\* | 100.0 ± 28.8 | 105.2 ± 30.4 | 129.7 ± 25.2 |
| scI/RI model (day 8) | | | | |
| F4/80 | 22.6 ± 3.4\*\*\* | 100.0 ± 23.9 | 121.8 ± 24.5 | 122.5 ± 23.4 |
| MCP-1 | 10.5 ± 7.2\*\*\*\* | 100.0 ± 28.5 | 97.8 ± 33.8 | 126.2 ± 35.6 |
| *SHAM n =6, all other groups n = 12; data are expressed as means ± SD percentage values calculated vs. placebo. Differences between placebo group were analyzed by one-way ANOVA with Dunnett’s corrections for multiple comparisons. Statistical significance was defined as p ≤ 0.05.* *Abbreviations: MCP-1 = monocyte chemoattractant protein, F4/80 =* *murine homolog of the EGF-like module-containing mucin-like hormone receptor-like 1 (EMR1).* | | | | |